A canadian perspective.

A canadian perspective. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A canadian perspective. Abstract Text:

N Otten,

Although the healthcare program in Canada is in many ways universal, there are several differences between the provinces. Two key federal bodies (the Health Protection Branch of Health Canada and the Patented Medicine Prices Review Board) are involved in the drug review process. In addition, the Canadian Coordinating Office for Health Technology Assessment (CCOHTA), an organization funded jointly by provinces and the federal government, reviews new or existing drugs at the request of provinces. Each province or territory and the federal government has its own drug plan or plans. The 10 Canadian provinces require a notice of compliance, information on pricing, and clinical and comparative information for submission of a new drug. Over the last 3 years, 8 of the 10 provinces have required pharmacoeconomic analyses to be added to the submissions. Four of the eight provinces requiring pharmacoeconomic evaluations have specified that these evaluations should be made according to the Canadian Coordinating Office for Health Technology Assessment guidelines. A review of the utilization patterns of lipid-lowering therapies is presented in this Canadian context. Statins comprised 80% of the lipid-lowering drug market in 1995. Prescribers use statins available in Canada interchangeably for all approved and nonapproved indications. The newest statin, atorvastatin, has attained a market share for new prescriptions equivalent to simvastatin and pravastatin, despite the lack of clinical outcome studies. CCOHTA reviewed the evidence of efficacy and effectiveness of statins, evaluated whether significant differences existed between statins, and analyzed published economic evaluations. It found that treatment of higher-risk patients with statins is more cost-effective than that of lower-risk subjects. The evaluation also concluded that the statins, as a class, probably act in reducing LDL and raising HDL, resulting in beneficial clinical outcomes.

A canadian perspective. Publishing Authors By Initials

N Otten,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A canadian perspective. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Value in health : the journal of the International

VOLUME: 1

Page Numbers: 218-23

Journal Abbreviation:

ISSN: 1098-3015

DAY: 5

MONTH: Nov

YEAR: 1998

A canadian perspective. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100883818

A canadian perspective. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A canadian perspective. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A canadian perspective.

AFFILIATION: Canadian Coordinating Office for Health Technology Assessment, Ottawa, Ontario, Canada. nicko@ccohta.ca

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Value Health

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A canadian perspective Related Publications

• A canadian perspective.
• A fungal growth model fitted to carbon-limited dynamics of Rhizoctonia solani.
• A visual pitfall: Persistent Mullerian duct syndrome (PMDS).
• Analysis of the antimicrobial activity of local anaesthetics used for dental analgesia.
• Biologic markers in neuroblastoma.
• Case files of the university of cincinnati fellowship in medical toxicology: two patients with acute lethal occupational exposure to hydrogen sulfide.
• Chronic, infantile, neurological, cutaneous, and articular syndrome in a neonate: a case report.
• Controlling propulsive forces in gait initiation in transfemoral amputees.
• Hyperpolarized gases--a new type of MR contrast agents?
• Illegitimacy moderates the effects of power on approach.
• Maxillomandibular fixation with Otten mini-hooks.
• Measurement and data-processing approach for estimating the spatial statistics of turbulence-induced index of refraction fluctuations in the upper atmosphere.
• Methodology issues in lipid pharmacoeconomic investigations. Reactor panel and open forum.
• Multi-joint dynamics and the development of movement control.
• Nerve growth factor as a mediator of information between effector organs and innervating neurons.
• Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
• Proprioceptive coordination of movement sequences in humans.
• Purpose in life in patients with rheumatoid arthritis.
• Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database.
• Stress-induced secretion of ACTH and corticosterone during development of spontaneous hypertension in rats.
• The Killer Immunoglobulin-Like Receptor (KIR) Group A Haplotype is Associated With Bronchiolitis Obliterans Syndrome After Lung Transplantation.
• The motor system: the whole and its parts.
• Towards automated diffraction tomography. Part II-Cell parameter determination.
• Unresolved maternal attachment representations, disrupted maternal behavior and disorganized attachment in infancy: links to toddler behavior problems.
• [Effects of war conditions on the frequency and the course of certain internal diseases.]
• [Experiences with MUMPS in the development of a laboratory system]
• [Intradermoreactions to histoplasmin in a Congolese population as compared with coccidioidin, blastomycin and tuberculin.]
• [Results of treatment with growth hormones in children with classical growth hormone deficiency]
• [Visceral leishmaniasis: a possible diagnosis in Belgium]